Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jul 17;4(1):e000154.
doi: 10.1136/bmjgast-2017-000154. eCollection 2017.

Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review

Gurpartap S Sidhu  1 , Andrew Go  2 , Bashar M Attar  1 , Hemant R Mutneja  1 , Shilpa Arora  1 , Sanjay A Patel  1
Affiliations

Rifaximin versus norfloxacin for prevention of spontaneous bacterial peritonitis: a systematic review

Gurpartap S Sidhu et al. BMJ Open Gastroenterol. .

Abstract

Aim: The aim of this systematic review is to evaluate the efficacy and safety of rifaximin in the prophylaxis of spontaneous bacterial peritonitis (SBP) as compared with norfloxacin.

Methods: We searched MEDLINE, CINAHL, Google Scholar and Cochrane databases from inception to January 2017. Reference lists of articles as well as conference proceedings were manually screened. We included studies that recruited patients with cirrhosis and ascites who met the criteria for primary or secondary SBP prophylaxis as defined by the European Association for the Study of the Liver and American Association for the Study of Liver Diseases. Two independent investigators reviewed the studies for eligibility, extracted the data and assessed study quality using the Cochrane risk of bias tool. The primary outcome was occurrence of SBP. Secondary outcomes included mortality and adverse events with therapy.

Results: Of the 435 studies identified, a total of five were included for full-text review. Four studies were eligible for the systematic review, three of which were randomised controlled trials and one was a prospective observational study. The population examined in majority of studies was primarily hepatitis C cirrhosis. The results of individual studies indicated either superior efficacy of rifaximin or no statistical difference between rifaximin and norfloxacin for SBP prophylaxis.

Conclusions: Moderate-quality evidence shows that long-term use of rifaximin appears to be a reasonable alternative to norfloxacin for SBP prevention in hepatitis C cirrhosis.

Keywords: ANTIBIOTIC THERAPY; ASCITES; CIRRHOSIS; PERITONITIS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA flow diagram.
Figure 2
Figure 2
Cochrane risk of bias tool.
See this image and copyright information in PMC

References

    1. Lozano R, Naghavi M, Foreman K et al. . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128. doi:10.1016/S0140-6736(12)61728-0 - DOI - PMC - PubMed
    1. Singal AK, Salameh H, Kamath PS. Prevalence and in-hospital mortality trends of infections among patients with cirrhosis: a nationwide study of hospitalised patients in the United States. Aliment Pharmacol Ther 2014;40:105–12. doi:10.1111/apt.12797 - DOI - PubMed
    1. Giannelli V, Di gregorio V, Iebba V et al. . Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis. World J Gastroenterol 2014;20:16795–810. doi:10.3748/wjg.v20.i45.16795 - DOI - PMC - PubMed
    1. Guarner C, Runyon BA, Young S et al. . Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997;26:1372–8. doi:10.1016/S0168-8278(97)80474-6 - DOI - PubMed
    1. Titó L, Rimola A, Ginès P et al. . Recurrence of spontaneous bacterial peritonitis in cirrhosis: frequency and predictive factors. Hepatology 1988;8:27–31. doi:10.1002/hep.1840080107 - DOI - PubMed

LinkOut - more resources